6.83
+0.04(+0.59%)
Currency In USD
Address
10880 Wilshire Boulevard
Los Angeles, CA 90024
United States of America
Phone
424 248 6500
Sector
Healthcare
Industry
Biotechnology
Employees
172
First IPO Date
April 24, 2012
| Name | Title | Pay | Year Born |
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary | 1.86M | 1970 |
| Douglas Hunt | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | 735,530 | 1965 |
| Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer | 854,153 | 1969 |
| Mariann Ohanesian | Senior Director of Investor Relations | 0 | N/A |
| Roger L. Storms | Senior Vice President of Sales | 0 | N/A |
| Heather Blaber | Senior Vice President of Marketing | 0 | N/A |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.